Rx drug information, pharmaceutical research, clinical trials, news, and more
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. [2014]
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. [2014]
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. [2013]
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. [2013]
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. [2008]
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. [2007]
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. [2007]
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. [2006]
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. [2010]
5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. [2010]
Clinical roundtable monograph. Overall survival and maintenance of MDS patients. [2009]
Use of hypomethylating agents in myelodysplastic syndromes. [2007]
DNA hypo-methylating agents and sickle cell disease. [2004]
Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. [2001]
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. [1998]
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). [1997]
The euphoria of hypomethylating agents in MDS and AML: is it justified? [2013]
Myelodysplasia: new approaches. [2013]
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. [2013]
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. [2015]
All Rights reserved - Copyright DrugLib.com, 2006-2017